Brawley: ACS prostate cancer screening guideline should say no to “mass screening”

From The Cancer Letter · 00:36:14

Show by The Cancer Letter

On Nov. 12, the American Cancer Society published strengthened prostate cancer screening guidelines, advising routine, age-based screening for all men over fifty and men at high risk over age 45. The strengthened recommendation comes after 30 years of advising men to discuss prostate-specific antigen, or PSA, testing, with a physician and weigh the potential benefits and harms, rather than treat screening as an unquestioned routine—a recommendation commonly referred to as “informed decisionmaking.”In last week’s issue of The Cancer Letter, Otis W. Brawley, Bloomberg Distinguished Professor of Oncology and Epidemiology at Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University, and Ian Schonman, MPH candidate at Johns Hopkins Bloomberg School of Public Health, wrote a perspective piece about the new guidelines. They explained that the updated recommendation is heavily influenced by the maturing of data from a clinical trial that began in the early 1990s that suggest that rigorous screening, diagnosis, and treatment can lead to a mortality reduction. However, the data also demonstrate the limitations and harms associated with screening and treatment.On this episode of The Cancer Letter Podcast, Brawley has a frank discussion with Paul Goldberg, editor and publisher of The Cancer Letter, about how screening can cause harm, and how ignoring that reality in messaging can further damage the public’s already brittle trust in science. “One of the reasons why I am so hell-bent on this issue of informed decision-making, acknowledging the harms, acknowledging the benefits, is we have a trust problem in the United States when it comes to science and medicine today, and if we are not open and honest about the pros and the cons, if we don't respect a man's right to choose or a woman's right to choose, we actually give them permission or reason why they should distrust us,” Brawley said. “And this is especially true in prostate cancer, where there's a lot of money to be made in screening.”According to Brawley, money can be made through prostate cancer treatment, through adult diapers, through artificial sphincters, penile prosthesis, and drugs for erectile dysfunction.There's a lot of money to be made out of this and a lot of opportunity for people to be taken advantage of, Brawley said. And the harms are not necessarily minimal.“I can point to a time when screening for neuroblastoma in children with a urine test ultimately led to harm in children,” Brawley said. “I can point to the 1960s when screening with chest X-ray for lung cancer ultimately led to more harm than benefit. And history has this way of repeating itself. We have hurt a large number of men with prostate cancer screening. We finally, I think, are onto some legitimate ways to handle prostate cancer screening in such a way that we can minimize the harm and maximize the benefit, and I just hope that we listen.”Brawley is not anti-screening, he said. “The previous guideline, which has my name on it, was a guideline that a lot of people had difficulty interpreting,” Brawley said. “This guideline I think is clear that there are harms, clear that there are some proven benefits. I think if you read it very carefully, it says that within the physician-patient relationship, the man needs to be informed, and that's good. I wish it said that louder. That's the only real criticism I have of this current guideline. I wish it said, ‘This should be within the physician-patient relationship,’ louder and I wish it said, ‘We should not be involved in mass screening.’"This episode is sponsored by Roswell Park Comprehensive Cancer Center. Learn more at roswellpark.org.A transcript of this podcast is available: ⁠https://cancerletter.com/podcastc/20261118-psa/⁠

More episodes of The Cancer Letter

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.